Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 18/20 | 0.53 |
| ▸ | NOS1 | P29475 | 4/20 | 0.53 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5340893 | 0.77 | NOS2 (0.48) | NOS2NOS1 | |
| SCHEMBL3569388 | 0.73 | NOS2 (0.60) | NOS2NOS1 | |
| SCHEMBL5340900 | 0.73 | NOS2 (0.65) | NOS2NOS1 | |
| Hydrochloric Acid SCHEMBL3571851 | 0.73 | NOS2 (0.60) | NOS2NOS1 | |
| SCHEMBL3562923 | 0.71 | NOS2 (0.58) | NOS2NOS1 | |
| SCHEMBL3561935 | 0.71 | NOS2 (0.51) | NOS2NOS1 | |
| SCHEMBL3556108 | 0.69 | NOS1 (0.55) | NOS2NOS1 | |
| SCHEMBL3560178 | 0.69 | NOS2 (1.00) | NOS2NOS1 | |
| SCHEMBL3561754 | 0.69 | NOS2 (0.53) | NOS2NOS1 | |
| SCHEMBL4884982 | 0.69 | NOS2 (0.61) | NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080293942-A1 | Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives | COUSINS RUSSELL D | 2008-11-27 | — | — | US | disclosed |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | NOS3, NOS2, NOS1 | NOS2 2/4885NOS1 3/4885ADAM17 2783/4885 |
| US-20080293942-A1 | Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives | NOS2, NOS1, NOS3 | NOS2 1/4885NOS1 2/4885ADAM17 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.